{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:17:38Z","timestamp":1793330258053,"version":"4.5.0"},"reference-count":749,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jacc.2024.02.014","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:22:11Z","timestamp":1715185331000},"page":"2324-2405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":422,"title":["2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"83","author":[{"given":"Steve R.","family":"Ommen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan M.","family":"Asif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seshadri","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Dearani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Epps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Evanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor A.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Joglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Mital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari S.","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Semsarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Times","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Burstein","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.02.014_bib1","series-title":"Clinical Practice Guidelines We Can Trust","article-title":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US)","year":"2011"},{"key":"10.1016\/j.jacc.2024.02.014_bib2","series-title":"Finding What Works in Health Care: Standards for Systematic Reviews","article-title":"Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US)","year":"2011"},{"key":"10.1016\/j.jacc.2024.02.014_bib3","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib4","series-title":"ACCF\/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF\/AHA Task Force on Practice Guidelines","year":"2010"},{"key":"10.1016\/j.jacc.2024.02.014_bib5","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jacc.2015.09.001","article-title":"Further evolution of the ACC\/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"67","author":"Halperin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib6","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2014.07.012","volume":"64","author":"Arnett","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib7","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jacc.2019.02.012","article-title":"Recent innovations, modifications, and evolution of ACC\/AHA clinical practice guidelines: an update for our constituencies: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Levine","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib8","series-title":"In: CADTH Search Filters Database","article-title":"Animal Studies\u2014Standard\u2014PubMed","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib9","series-title":"In: CADTH Search Filters Database","article-title":"Guidelines\u2014Broad\u2014PubMed","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib10","series-title":"In: CADTH Search Filters Database","article-title":"Guidelines\u2014Standard\u2014PubMed","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib11","series-title":"CADTH Search Filters Database","article-title":"RCT \/ CCT\u2014PubMed","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib12","series-title":"CADTH Search Filters Database","article-title":"SR \/ MA \/ HTA \/ ITC\u2014PubMed","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib13","author":"Donahue"},{"key":"10.1016\/j.jacc.2024.02.014_bib14","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib15","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib16","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib20","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib21","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib22","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib23","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib24","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib25","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jacc.2012.12.014","volume":"61","author":"Epstein","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib26","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib27","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jacc.2018.10.044","volume":"74","author":"Kusumoto","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/CIR.0b013e31820faaf8","article-title":"Effectiveness-based guidelines for the prevention of cardiovascular disease in women\u20142011 update: a guideline from the American Heart Association","volume":"123","author":"Mosca","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib29","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"58","author":"Smith","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib30","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.jacc.2010.09.001","article-title":"2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"56","author":"Greenland","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.0000110061.06674.ca","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials","volume":"43","author":"Jones","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2024.02.014_bib32","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.jacc.2018.10.007","volume":"73","author":"Nishimura","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3750879","article-title":"Disparities in the diagnosis of hypertrophic obstructive cardiomyopathy: a narrative review of current literature","volume":"2018","author":"Burns","year":"2018","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.jacc.2024.02.014_bib34","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib35","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.amjcard.2016.02.044","article-title":"Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States","volume":"117","author":"Maron","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamacardio.2019.4638","article-title":"Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy","volume":"5","author":"Eberly","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib41","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0025-6196(11)64198-0","article-title":"Dynamic left ventricular outflow tract obstruction in acute coronary syndromes","volume":"75","author":"Keegan","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2024.02.014_bib43","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.amjcard.2020.02.013","article-title":"Distinctive hypertrophic cardiomyopathy anatomy and obstructive physiology in patients admitted with Takotsubo Syndrome","volume":"125","author":"Sherrid","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib44","first-page":"364","article-title":"Hypertrophic cardiomyopathy: clinical update","volume":"6","author":"Geske","year":"2018","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.02.014_bib45","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2024.02.014_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib47","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib48","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","article-title":"Clinical and mechanistic insights into the genetics of cardiomyopathy","volume":"68","author":"Burke","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect","volume":"53","author":"Tadros","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib51","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib52","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ehjqcco\/qcac006","article-title":"Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy\/Myocarditis Registry","volume":"9","author":"Lopes","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jacc.2024.02.014_bib56","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib57","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jcin.2011.02.014","article-title":"Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy","volume":"4","author":"Geske","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2024.02.014_bib58","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/echo.12951","article-title":"Postprandial hemodynamics in hypertrophic cardiomyopathy","volume":"32","author":"Adams","year":"2015","journal-title":"Echocardiography"},{"key":"10.1016\/j.jacc.2024.02.014_bib59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/ehjci\/jex215","article-title":"Marked respiratory-related fluctuations in left ventricular outflow tract gradients in hypertrophic obstructive cardiomyopathy: an observational study","volume":"19","author":"Jain","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib60","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.amjcard.2017.08.047","article-title":"Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy","volume":"120","author":"Ayoub","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib61","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.amjcard.2010.06.057","article-title":"Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy","volume":"106","author":"Nistri","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjci\/jew313","article-title":"Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study","volume":"19","author":"Reant","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.echo.2010.10.006","article-title":"Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity","volume":"24","author":"Joshi","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib64","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.jacc.2013.02.079","article-title":"Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy","volume":"61","author":"Feiner","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib65","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/01.CIR.86.5.1429","article-title":"Dynamic intraventricular obstruction during dobutamine stress echocardiography. A new observation","volume":"86","author":"Pellikka","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib66","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.amjcard.2007.09.111","article-title":"Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy","volume":"101","author":"Elesber","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib67","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0735-1097(83)80235-6","article-title":"Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: altered left ventricular loading or improved muscle inactivation?","volume":"2","author":"Paulus","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib68","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCIMAGING.111.968859","article-title":"Exercise response in hypertrophic cardiomyopathy: blunted left ventricular deformational and twisting reserve with altered systolic-diastolic coupling","volume":"5","author":"Soullier","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib69","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jcmg.2018.02.002","article-title":"Myocardial stiffness evaluation using noninvasive shear wave imaging in healthy and hypertrophic cardiomyopathic adults","volume":"12","author":"Villemain","year":"2019","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib70","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCGENETICS.109.862128","article-title":"Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy","volume":"2","author":"Ho","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib71","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/eurheartj\/ehv120","article-title":"Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction","volume":"36","author":"Dass","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","article-title":"Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes","volume":"7","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.110.985812","article-title":"Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy","volume":"124","author":"Maron","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib74","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/ehjci\/jey095","article-title":"Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers","volume":"19","author":"Groarke","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib75","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","article-title":"The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context","volume":"67","author":"Sherrid","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.echo.2018.10.011","article-title":"Accuracy of jet direction on Doppler echocardiography in identifying the etiology of mitral regurgitation in obstructive hypertrophic cardiomyopathy","volume":"32","author":"Hang","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib77","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jtcvs.2018.11.148","article-title":"Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center","volume":"157","author":"Hodges","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib78","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jacc.2016.07.735","article-title":"Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures","volume":"68","author":"Hong","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib79","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/01.CIR.71.2.234","article-title":"Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures","volume":"71","author":"Cannon","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib80","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0735-1097(86)80181-4","article-title":"Intramural (\u201csmall vessel\u201d) coronary artery disease in hypertrophic cardiomyopathy","volume":"8","author":"Maron","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib81","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacc.2012.12.024","article-title":"Blunted myocardial oxygenation response during vasodilator stress in patients with hypertrophic cardiomyopathy","volume":"61","author":"Karamitsos","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib82","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jacc.2016.07.751","article-title":"Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance","volume":"68","author":"Raphael","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib83","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1161\/01.CIR.0000097110.55312.BF","article-title":"Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease","volume":"108","author":"Sorajja","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib84","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib85","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.echo.2011.03.002","article-title":"Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching","volume":"24","author":"Binder","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13958-0","article-title":"Cardiovascular consequences of myocardial bridging: a meta-analysis and meta-regression","volume":"7","author":"Hostiuc","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2024.02.014_bib87","doi-asserted-by":"crossref","first-page":"H1282","DOI":"10.1152\/ajpheart.00466.2019","article-title":"Hemodynamic effects of myocardial bridging in patients with hypertrophic cardiomyopathy","volume":"317","author":"Sharzehee","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/MAJ.0000000000000194","article-title":"Myocardial bridging as a common phenotype of hypertrophic cardiomyopathy has no effect on prognosis","volume":"347","author":"Tian","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jacc.2024.02.014_bib89","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM199810223391704","article-title":"Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death","volume":"339","author":"Yetman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib90","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000486276","article-title":"Clinical outcomes of myocardial bridging versus no myocardial bridging in patients with apical hypertrophic cardiomyopathy","volume":"139","author":"Zhai","year":"2018","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2024.02.014_bib91","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.amjcard.2013.11.062","article-title":"Heart rate recovery in patients with hypertrophic cardiomyopathy","volume":"113","author":"Patel","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib92","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1161\/01.CIR.82.6.1995","article-title":"Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy","volume":"82","author":"Frenneaux","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib93","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1161\/01.CIR.96.9.2987","article-title":"Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy","volume":"96","author":"Sadoul","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib94","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/S0735-1097(99)00094-7","article-title":"Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy","volume":"33","author":"Olivotto","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib95","series-title":"Strategy 6I: Shared Decisionmaking. The CAHPS Ambulatory Care Improvement Guide: Practical Strategies for Improving Patient Experience","year":"2017"},{"key":"10.1016\/j.jacc.2024.02.014_bib96","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/BF02595921","article-title":"Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes","volume":"3","author":"Greenfield","year":"1988","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib97","doi-asserted-by":"crossref","first-page":"520","DOI":"10.7326\/0003-4819-102-4-520","article-title":"Expanding patient involvement in care. Effects on patient outcomes","volume":"102","author":"Greenfield","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib98","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/00005650-198903001-00010","article-title":"Assessing the effects of physician-patient interactions on the outcomes of chronic disease","volume":"27","author":"Kaplan","year":"1989","journal-title":"Med Care"},{"key":"10.1016\/j.jacc.2024.02.014_bib99","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0277-9536(98)00059-8","article-title":"Patient participation in decision-making","volume":"47","author":"Guadagnoli","year":"1998","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib100","first-page":"CD006732","article-title":"Interventions for increasing the use of shared decision making by healthcare professionals","volume":"7","author":"Legare","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2024.02.014_bib101","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib102","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.amjcard.2014.07.075","article-title":"Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010])","volume":"114","author":"Panaich","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib103","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","article-title":"Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"126","author":"Sorajja","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2017.6","article-title":"Shared decision-making in HCM","volume":"14","author":"Maron","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib105","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/eurheartj\/ehx370","article-title":"Standards defining a \u201cheart valve centre\u201d: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint","volume":"38","author":"Chambers","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib106","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib108","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","article-title":"Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1540-8167.2008.01366.x","article-title":"Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm","volume":"20","author":"Lim","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCEP.110.957290","article-title":"Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy","volume":"4","author":"Dukkipati","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib112","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjcard.2017.12.044","article-title":"Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy","volume":"121","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib113","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/CIRCHEARTFAILURE.114.001843","article-title":"Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy","volume":"8","author":"Pasqualucci","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib114","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/ehf2.14345","article-title":"Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care","volume":"10","author":"Garmany","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib115","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.jacc.2018.10.007","volume":"73","author":"Nishimura","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib116","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000504215","article-title":"Impact of septal myectomy volume on mitral-valve replacement rate in hypertrophic cardiomyopathy patients","volume":"145","author":"Polanco","year":"2020","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2024.02.014_bib117","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mayocp.2018.07.022","article-title":"Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery","volume":"94","author":"Holst","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2024.02.014_bib118","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib119","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.hrthm.2011.07.017","article-title":"The emerging role of the cardiac genetic counselor","volume":"8","author":"Ingles","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib120","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000054","article-title":"Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association","volume":"12","author":"Ahmad","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib121","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001896","article-title":"Outcomes of contemporary family screening in hypertrophic cardiomyopathy","volume":"11","author":"van Velzen","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib122","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/CIRCULATIONAHA.114.013478","article-title":"Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons","volume":"132","author":"Ranthe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib123","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/eurheartj\/ehz396","article-title":"Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?","volume":"40","author":"Lafreniere-Roula","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib124","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.amjcard.2006.07.029","article-title":"Determinants for clinical diagnosis of hypertrophic cardiomyopathy","volume":"98","author":"Adabag","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jcmg.2008.09.002","article-title":"Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies","volume":"1","author":"Afonso","year":"2008","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib126","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/0735-1097(95)00390-8","article-title":"Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients","volume":"26","author":"Klues","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0033-0620(85)90024-6","article-title":"Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review","volume":"28","author":"Wigle","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2024.02.014_bib128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0735-1097(83)80269-1","article-title":"Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study","volume":"2","author":"Shapiro","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.echo.2011.03.006","article-title":"American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy","volume":"24","author":"Nagueh","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib130","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","article-title":"Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy","volume":"31","author":"Melacini","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib131","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/hrt.2003.031161","article-title":"Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy","volume":"91","author":"Thaman","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib132","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib133","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","article-title":"Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging","volume":"5","author":"Olivotto","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib134","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2012.03.076","article-title":"Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy","volume":"60","author":"Todiere","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib135","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/europace\/euz118","article-title":"A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"21","author":"Norrish","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib136","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib137","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jacc.2010.11.002","volume":"57","author":"Douglas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib138","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib139","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","article-title":"Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy","volume":"111","author":"Woo","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib140","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.107.698985","article-title":"Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization","volume":"116","author":"Geske","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib141","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.echo.2018.01.022","article-title":"Standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"31","author":"Kumar","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib142","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0002-9149(99)80416-0","article-title":"Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy","volume":"75","author":"Marwick","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib143","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.echo.2010.10.006","article-title":"Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity","volume":"24","author":"Joshi","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib144","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib145","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.amjcard.2017.08.047","article-title":"Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy","volume":"120","author":"Ayoub","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib146","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/ejechocard\/jeq063","article-title":"Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"11","author":"Jensen","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib147","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjci\/jew313","article-title":"Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study","volume":"19","author":"Reant","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib148","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/hrt.2007.126003","article-title":"Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy","volume":"94","author":"Shah","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib149","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0735-1097(92)90135-A","article-title":"Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making","volume":"20","author":"Grigg","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib150","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/0735-1097(92)90359-U","article-title":"Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy","volume":"20","author":"Marwick","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib151","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.echo.2017.11.016","article-title":"Intraoperative two- and three-dimensional transesophageal echocardiography in combined myectomy-mitral operations for hypertrophic cardiomyopathy","volume":"31","author":"Nampiaparampil","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib152","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0002-9149(02)02694-2","article-title":"Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy","volume":"90","author":"Ommen","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib153","first-page":"462","article-title":"Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area","volume":"47","author":"Faber","year":"1999","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.02.014_bib154","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1067\/mje.2000.108250","article-title":"Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring","volume":"13","author":"Faber","year":"2000","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib155","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jcmg.2015.04.006","article-title":"Role of imaging in the evaluation of patients at risk for sudden cardiac death: genotype-phenotype intersection","volume":"8","author":"Nagueh","year":"2015","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib156","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.euje.2004.01.001","article-title":"Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience","volume":"5","author":"Faber","year":"2004","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib157","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/euhj.1999.1692","volume":"20","author":"Kuhn","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib158","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.107.738740","article-title":"Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"118","author":"Sorajja","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib159","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/01.CIR.98.22.2415","article-title":"Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography","volume":"98","author":"Faber","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib160","first-page":"1994","article-title":"Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery","volume":"38","author":"Qin","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib161","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib162","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.111.090514","article-title":"Penetrance of hypertrophic cardiomyopathy in children and adolescents","volume":"127","author":"Jensen","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib163","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/eurheartj\/ehz396","article-title":"Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?","volume":"40","author":"Lafreniere-Roula","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib164","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.118.037264","article-title":"Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy","volume":"139","author":"Maurizi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib165","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.118.038846","article-title":"Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives: evidence for a change in paradigm","volume":"140","author":"Norrish","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib166","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jpeds.2017.03.033","article-title":"Penetrance of hypertrophic cardiomyopathy in children who are mutation positive","volume":"188","author":"Vermeer","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2024.02.014_bib167","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0894-7317(00)90026-9","article-title":"Apical hypertrophic cardiomyopathy: echocardiographic diagnosis with the use of intravenous contrast image enhancement","volume":"13","author":"Thanigaraj","year":"2000","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib168","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","article-title":"Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update","volume":"31","author":"Porter","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib169","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.jacc.2013.02.079","article-title":"Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy","volume":"61","author":"Feiner","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2006.07.179","article-title":"Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances","volume":"119","author":"Faber","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib171","first-page":"896","article-title":"A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.02.014_bib172","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/eurheartj\/ehq271","article-title":"Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"31","author":"Charron","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib173","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2018180339","article-title":"Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy: cardiac MR feature tracking","volume":"290","author":"Vigneault","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2024.02.014_bib174","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/01.CIR.0000084500.72232.8D","article-title":"Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease","volume":"108","author":"Nagueh","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib175","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","article-title":"Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy","volume":"105","author":"Ho","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib176","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/CIRCHEARTFAILURE.108.817346","article-title":"Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia\/cardiomyopathy","volume":"2","author":"Hershberger","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib177","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2009.05.006","article-title":"Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance","volume":"54","author":"Maron","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib178","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.104.507723","article-title":"Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy","volume":"112","author":"Rickers","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib179","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/hrt.2003.014969","article-title":"Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography","volume":"90","author":"Moon","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib180","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006309","article-title":"Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy","volume":"10","author":"Hindieh","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib181","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10554-016-0858-4","article-title":"Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography","volume":"32","author":"Corona-Villalobos","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib182","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.amjcard.2016.11.010","article-title":"Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography","volume":"119","author":"Bois","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib183","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005372","article-title":"How to image hypertrophic cardiomyopathy","volume":"10","author":"Maron","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib184","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib185","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10554-013-0355-y","article-title":"Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI","volume":"30","author":"Kebed","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib186","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.amjcard.2010.01.367","article-title":"Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance","volume":"105","author":"Maron","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib187","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib188","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib189","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function","volume":"72","author":"Mentias","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib190","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1136\/heartjnl-2013-305471","article-title":"Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy","volume":"100","author":"Ismail","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib191","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib192","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003132","article-title":"Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib193","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2018.06.055","article-title":"Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy","volume":"122","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib194","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","article-title":"The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context","volume":"67","author":"Sherrid","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib195","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/hrt.2007.118018","article-title":"Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"94","author":"Kwon","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib196","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.amjcard.2013.01.340","article-title":"Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management","volume":"111","author":"Rowin","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib197","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.109.854026","article-title":"Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy","volume":"3","author":"Rubinshtein","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib198","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2012.03.076","article-title":"Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy","volume":"60","author":"Todiere","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib199","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jacc.2010.11.002","volume":"57","author":"Douglas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.echo.2011.03.006","article-title":"American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy","volume":"24","author":"Nagueh","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib201","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10554-013-0358-8","article-title":"Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients","volume":"30","author":"Langer","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib202","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ejrad.2014.05.035","article-title":"Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multidetector computed tomography versus magnetic resonance imaging","volume":"83","author":"Zhao","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1542-474X.2001.tb00118.x","article-title":"The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited","volume":"6","author":"Maron","year":"2001","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib204","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/0002-9149(89)90187-2","article-title":"Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood","volume":"63","author":"Panza","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib205","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjsports-2016-097438","article-title":"Accuracy of the ECG for differential diagnosis between hypertrophic cardiomyopathy and athlete\u2019s heart: comparison between the European Society of Cardiology (2010) and International (2017) criteria","volume":"52","author":"Zorzi","year":"2018","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib206","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0002-9149(81)90604-4","article-title":"Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study","volume":"48","author":"Maron","year":"1981","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib207","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib208","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2004.11.043","article-title":"Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy","volume":"45","author":"Adabag","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib209","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jce.12982","article-title":"High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device","volume":"27","author":"Wilke","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjcard.2016.08.092","article-title":"Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy","volume":"119","author":"van Velzen","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib211","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib212","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.amjcard.2017.02.040","article-title":"Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy","volume":"119","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib213","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.02.014_bib214","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: the HCM-AF Score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib215","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.hrthm.2019.07.019","article-title":"The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy","volume":"17","author":"Finocchiaro","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib216","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.jacc.2015.09.035","volume":"66","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib217","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004604","article-title":"Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy","volume":"10","author":"Wang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib218","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.amjcard.2016.07.043","article-title":"Usefulness of 14-day Holter for detection of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"118","author":"Weissler-Snir","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib219","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.107.698985","article-title":"Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization","volume":"116","author":"Geske","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib220","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jcin.2011.02.014","article-title":"Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy","volume":"4","author":"Geske","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2024.02.014_bib221","first-page":"962","article-title":"Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction","volume":"88","author":"Prasad","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.02.014_bib222","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.amjcard.2007.09.111","article-title":"Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy","volume":"101","author":"Elesber","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib223","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1161\/01.CIR.0000097110.55312.BF","article-title":"Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease","volume":"108","author":"Sorajja","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib224","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtcvs.2013.06.046","article-title":"Assessment of coronary artery disease risk in 5463 patients undergoing cardiac surgery: when is preoperative coronary angiography necessary?","volume":"146","author":"Thalji","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.echo.2010.10.006","article-title":"Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity","volume":"24","author":"Joshi","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib226","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib227","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.amjcard.2017.08.047","article-title":"Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy","volume":"120","author":"Ayoub","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib228","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/ejechocard\/jeq063","article-title":"Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"11","author":"Jensen","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib229","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjci\/jew313","article-title":"Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study","volume":"19","author":"Reant","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib230","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/hrt.2007.126003","article-title":"Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy","volume":"94","author":"Shah","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib231","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib232","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1253\/circj.CJ-16-0432","article-title":"Heart failure progression in hypertrophic cardiomyopathy\u2014possible insights from cardiopulmonary exercise testing","volume":"80","author":"Magr\u00ec","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2024.02.014_bib233","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3390\/jcm10112312","article-title":"Cardiopulmonary exercise test in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"10","author":"Bayonas-Ruiz","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib234","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.122.062699","article-title":"The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy","volume":"147","author":"Conway","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib235","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/jcm10071347","article-title":"Prognostic value of reduced heart rate reserve during exercise in hypertrophic cardiomyopathy.","volume":"10","author":"Ciampi","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib236","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2021.06.051","article-title":"Prognostic relevance of exercise testing in hypertrophic cardiomyopathy. A systematic review","volume":"339","author":"Rodrigues","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib237","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib238","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0002-9149(99)80416-0","article-title":"Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy","volume":"75","author":"Marwick","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2020.10.062","article-title":"Cardiopulmonary exercise test in patients with obstructive hypertrophic cardiomyopathy","author":"Cui","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib240","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/2047487319898106","article-title":"Predictors of exercise capacity following septal myectomy in patients with hypertrophic cardiomyopathy","volume":"27","author":"Smith","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib241","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","article-title":"Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy","volume":"111","author":"Woo","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib242","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.jacc.2013.02.079","article-title":"Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy","volume":"61","author":"Feiner","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib243","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000054","article-title":"Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association","volume":"12","author":"Ahmad","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib244","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/eurheartj\/ehq271","article-title":"Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"31","author":"Charron","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib245","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib246","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/gim.2013.44","article-title":"Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy","volume":"15","author":"Ingles","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib247","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001896","article-title":"Outcomes of contemporary family screening in hypertrophic cardiomyopathy","volume":"11","author":"van Velzen","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib248","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/CIRCULATIONAHA.114.013478","article-title":"Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons","volume":"132","author":"Ranthe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib249","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/eurheartj\/ehz396","article-title":"Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?","volume":"40","author":"Lafreniere-Roula","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib250","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/gim.2014.205","article-title":"Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity","volume":"17","author":"Alfares","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib251","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacc.2018.04.078","article-title":"Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy","volume":"72","author":"Bagnall","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib252","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib253","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002460","article-title":"Evaluating the clinical validity of hypertrophic cardiomyopathy genes","volume":"12","author":"Ingles","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib254","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.117.001916","article-title":"Pathogenicity of hypertrophic cardiomyopathy variants: a path forward together","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib255","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.2009.371","article-title":"Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy","volume":"301","author":"Maron","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib256","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCIMAGING.110.957936","article-title":"Imaging phenotype versus genotype in hypertrophic cardiomyopathy","volume":"4","author":"Desai","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib257","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.hrthm.2011.07.017","article-title":"The emerging role of the cardiac genetic counselor","volume":"8","author":"Ingles","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib258","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib259","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cge.13024","article-title":"Clinical genetic testing in pediatric cardiomyopathy: is bigger better?","volume":"93","author":"Ouellette","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib260","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.111.090514","article-title":"Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing","volume":"127","author":"Jensen","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib261","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa075463","article-title":"Shared genetic causes of cardiac hypertrophy in children and adults","volume":"358","author":"Morita","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib262","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurheartj\/ehr092","article-title":"Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy","volume":"32","author":"Christiaans","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib263","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/eurheartj\/ehv063","article-title":"Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives","volume":"36","author":"Semsarian","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib264","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa1510687","article-title":"A prospective study of sudden cardiac death among children and young adults","volume":"374","author":"Bagnall","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib265","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/gim.2013.138","article-title":"Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment","volume":"16","author":"Das","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib266","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMsa1507092","article-title":"Genetic misdiagnoses and the potential for health disparities","volume":"375","author":"Manrai","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib267","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib268","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib269","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1136\/jmg.2005.033886","article-title":"Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling","volume":"42","author":"Ingles","year":"2005","journal-title":"J Med Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib270","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.118.038846","article-title":"Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives: evidence for a change in paradigm","volume":"140","author":"Norrish","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib271","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/gim.2012.19","article-title":"Communicating new knowledge on previously reported genetic variants","volume":"14","author":"Aronson","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib272","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib273","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41436-018-0391-z","article-title":"Patient re-contact after revision of genomic test results: points to consider\u2014a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"David","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib274","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41436-019-0478-1","article-title":"Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"Deignan","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib275","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tcm.2016.04.010","article-title":"Interdisciplinary psychosocial care for families with inherited cardiovascular diseases","volume":"26","author":"Caleshu","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib276","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib277","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fcvm.2017.00072","article-title":"Molecular autopsy for sudden death in the young: is data aggregation the key?","volume":"4","author":"Rueda","year":"2017","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib278","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/jama.2016.11445","article-title":"Molecular autopsy for sudden unexpected death","volume":"316","author":"Torkamani","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib279","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fcvm.2016.00020","article-title":"Clinical genetic testing for the cardiomyopathies and arrhythmias: a systematic framework for establishing clinical validity and addressing genotypic and phenotypic heterogeneity","volume":"3","author":"Garcia","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib281","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.111.090514","article-title":"Penetrance of hypertrophic cardiomyopathy in children and adolescents","volume":"127","author":"Jensen","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib282","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/eurheartj\/ehz396","article-title":"Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?","volume":"40","author":"Lafreniere-Roula","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib283","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.118.037264","article-title":"Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy","volume":"139","author":"Maurizi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib284","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.118.038846","article-title":"Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives: evidence for a change in paradigm","volume":"140","author":"Norrish","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jpeds.2017.03.033","article-title":"Penetrance of hypertrophic cardiomyopathy in children who are mutation positive","volume":"188","author":"Vermeer","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2024.02.014_bib286","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurheartj\/ehr092","article-title":"Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy","volume":"32","author":"Christiaans","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib287","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jamacardio.2023.1042","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"8","author":"Lampert","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib288","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijcard.2011.07.095","article-title":"Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy","volume":"152","author":"Gray","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib289","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/CIRCIMAGING.114.002411","article-title":"Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy","volume":"7","author":"Captur","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamacardio.2016.5670","article-title":"The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: findings from the HCMNet study","volume":"2","author":"Ho","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib291","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2018180339","article-title":"Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy: cardiac MR feature tracking","volume":"290","author":"Vigneault","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2024.02.014_bib292","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.amjcard.2018.08.008","article-title":"Multilayer myocardial mechanics in genotype-positive left ventricular hypertrophy-negative patients with hypertrophic cardiomyopathy","volume":"122","author":"Williams","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib293","first-page":"180","article-title":"Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression","volume":"3","author":"Ho","year":"2015","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.02.014_bib294","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib295","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/CIRCULATIONAHA.117.030437","article-title":"International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)","volume":"137","author":"O'Mahony","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib296","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(99)00056-X","article-title":"Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"33","author":"Elliott","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib297","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib298","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","article-title":"Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy","volume":"106","author":"Bos","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib299","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/eurheartj\/ehq308","article-title":"Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up","volume":"31","author":"Dimitrow","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib300","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib301","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2004.12.067","article-title":"The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms","volume":"45","author":"Autore","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib302","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","article-title":"Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy","volume":"357","author":"Elliott","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.02.014_bib303","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib304","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib305","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jjcc.2014.02.011","article-title":"Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography","volume":"64","author":"Ichida","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib306","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib307","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004604","article-title":"Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy","volume":"10","author":"Wang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib308","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10554-016-0858-4","article-title":"Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography","volume":"32","author":"Corona-Villalobos","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib309","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.amjcard.2016.11.010","article-title":"Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography","volume":"119","author":"Bois","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib310","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.amjcard.2010.01.367","article-title":"Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance","volume":"105","author":"Maron","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib311","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib312","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib313","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function","volume":"72","author":"Mentias","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib314","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1136\/heartjnl-2013-305471","article-title":"Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy","volume":"100","author":"Ismail","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib315","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O\u2019Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib316","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.echo.2011.03.002","article-title":"Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching","volume":"24","author":"Binder","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib317","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib318","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Insights from the SHaRe Registry","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib319","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.298.4.405","article-title":"Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"298","author":"Maron","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib320","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ahj.2013.06.009","article-title":"Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications","volume":"166","author":"Vriesendorp","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib321","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.117.032838","article-title":"Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy","volume":"137","author":"Wells","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib322","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","article-title":"Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy","volume":"46","author":"Olivotto","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib323","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0735-1097(00)01003-2","article-title":"Sudden death in hypertrophic cardiomyopathy: identification of high risk patients","volume":"36","author":"Elliott","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib324","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib325","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.112.136085","article-title":"Risk stratification and outcome of patients with hypertrophic cardiomyopathy \u226560 years of age","volume":"127","author":"Maron","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib326","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/eurheartj\/ehn122","article-title":"Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy","volume":"29","author":"Ostman-Smith","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib327","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-10-0921","article-title":"Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"74","author":"Maron","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2024.02.014_bib328","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib329","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jamacardio.2019.2861","article-title":"Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)","volume":"4","author":"Norrish","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib330","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/clc.4960130208","article-title":"Long-term prognosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less than or equal to 14 years at diagnosis","volume":"13","author":"Romeo","year":"1990","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib331","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(98)00493-8","article-title":"Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy","volume":"32","author":"Yetman","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib332","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/01.CIR.0000124723.16433.31","article-title":"Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy","volume":"109","author":"McMahon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib333","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1161\/CIRCULATIONAHA.104.530303","article-title":"Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study","volume":"112","author":"Nugent","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib334","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S1047951105001824","article-title":"Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly","volume":"15","author":"Ostman-Smith","year":"2005","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jacc.2024.02.014_bib335","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.106.621185","article-title":"Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry","volume":"115","author":"Colan","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib336","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/hrt.2006.094730","article-title":"Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy","volume":"93","author":"Kaski","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib337","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jacc.2009.03.051","article-title":"Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children","volume":"54","author":"Decker","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib338","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00246-011-0106-6","article-title":"Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy","volume":"33","author":"Maskatia","year":"2012","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib339","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00246-011-9967-y","article-title":"Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events","volume":"32","author":"Moak","year":"2011","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib340","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.athoracsur.2011.10.032","article-title":"Hypertrophic cardiomyopathy in childhood: disease natural history, impact of obstruction, and its influence on survival","volume":"93","author":"Hickey","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib341","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/CIRCHEARTFAILURE.113.000414","article-title":"Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy","volume":"6","author":"Chaowu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib342","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/S0140-6736(13)61685-2","article-title":"Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry","volume":"382","author":"Lipshultz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.02.014_bib343","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00246-013-0676-6","article-title":"Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study","volume":"34","author":"Kamp","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib344","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2013.01.037","article-title":"Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy","volume":"61","author":"Maron","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib345","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.amjcard.2013.12.034","article-title":"Clinical significance of late gadolinium enhancement in patients <20 years of age with hypertrophic cardiomyopathy","volume":"113","author":"Smith","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib346","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1017\/S1047951113001030","article-title":"Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients","volume":"24","author":"El-Saiedi","year":"2014","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jacc.2024.02.014_bib347","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.jacc.2015.03.552","article-title":"Sudden death in childhood cardiomyopathy: results from a long-term national population-based study","volume":"65","author":"Bharucha","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib348","doi-asserted-by":"crossref","first-page":"E258","DOI":"10.1111\/chd.12286","article-title":"Distribution of hypertrophy and late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy","volume":"10","author":"Windram","year":"2015","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.jacc.2024.02.014_bib349","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00246-015-1298-y","article-title":"Predictors of long-term outcome in children with hypertrophic cardiomyopathy","volume":"37","author":"Zi\u00f3\u0142kowska","year":"2016","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib350","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib351","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib352","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib353","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/europace\/euz118","article-title":"A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"21","author":"Norrish","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib354","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/2047487317702519","article-title":"Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"24","author":"Norrish","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib355","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/eurjpc\/zwab181","article-title":"External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"29","author":"Norrish","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib356","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.122.062699","article-title":"The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy","volume":"147","author":"Conway","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib357","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib358","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jamacardio.2019.2861","article-title":"Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)","volume":"4","author":"Norrish","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib359","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib360","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib361","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/europace\/euz118","article-title":"A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"21","author":"Norrish","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib362","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/2047487317702519","article-title":"Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"24","author":"Norrish","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib363","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.115.017633","article-title":"Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib364","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.amjcard.2020.04.042","article-title":"Prediction and prevention of sudden death in young patients (<20 years) with hypertrophic cardiomyopathy","volume":"128","author":"Rowin","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib365","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/CIRCHEARTFAILURE.113.000414","article-title":"Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy","volume":"6","author":"Chaowu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib366","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.amjcard.2013.12.034","article-title":"Clinical significance of late gadolinium enhancement in patients <20 years of age with hypertrophic cardiomyopathy","volume":"113","author":"Smith","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib367","doi-asserted-by":"crossref","first-page":"E258","DOI":"10.1111\/chd.12286","article-title":"Distribution of hypertrophy and late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy","volume":"10","author":"Windram","year":"2015","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.jacc.2024.02.014_bib368","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/eurjpc\/zwab181","article-title":"External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"29","author":"Norrish","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib369","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.jacc.2015.03.552","article-title":"Sudden death in childhood cardiomyopathy: results from a long-term national population-based study","volume":"65","author":"Bharucha","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib370","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib371","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib372","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jjcc.2014.02.011","article-title":"Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography","volume":"64","author":"Ichida","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib373","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10554-016-0858-4","article-title":"Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography","volume":"32","author":"Corona-Villalobos","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib374","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.amjcard.2016.11.010","article-title":"Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography","volume":"119","author":"Bois","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib375","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.amjcard.2010.01.367","article-title":"Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance","volume":"105","author":"Maron","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib376","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib377","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib378","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function","volume":"72","author":"Mentias","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib379","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib380","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib381","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1136\/heartjnl-2013-305471","article-title":"Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy","volume":"100","author":"Ismail","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib382","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib383","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib384","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib385","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.122.062699","article-title":"The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy","volume":"147","author":"Conway","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib386","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(99)00056-X","article-title":"Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"33","author":"Elliott","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib387","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","article-title":"Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy","volume":"106","author":"Bos","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib388","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib389","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","article-title":"Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy","volume":"357","author":"Elliott","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.02.014_bib390","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib391","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib392","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004604","article-title":"Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy","volume":"10","author":"Wang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib393","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S1047951105001824","article-title":"Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly","volume":"15","author":"Ostman-Smith","year":"2005","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jacc.2024.02.014_bib395","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2017.6","article-title":"Shared decision-making in HCM","volume":"14","author":"Maron","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib396","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib397","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2012-303271","volume":"99","author":"O'Mahony","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib398","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.298.4.405","article-title":"Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"298","author":"Maron","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib399","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ahj.2013.06.009","article-title":"Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications","volume":"166","author":"Vriesendorp","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib400","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(99)00056-X","article-title":"Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"33","author":"Elliott","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib401","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib402","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","article-title":"Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy","volume":"106","author":"Bos","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib403","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/eurheartj\/ehq308","article-title":"Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up","volume":"31","author":"Dimitrow","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib404","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib405","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2004.12.067","article-title":"The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms","volume":"45","author":"Autore","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib406","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","article-title":"Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy","volume":"357","author":"Elliott","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.02.014_bib407","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib408","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib409","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jjcc.2014.02.011","article-title":"Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography","volume":"64","author":"Ichida","year":"2014","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib410","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib411","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004604","article-title":"Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy","volume":"10","author":"Wang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib412","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1136\/heartjnl-2013-305471","article-title":"Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy","volume":"100","author":"Ismail","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib413","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O'Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib414","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib415","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib416","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2013.01.037","article-title":"Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy","volume":"61","author":"Maron","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib417","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/2047487317702519","article-title":"Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"24","author":"Norrish","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib418","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00246-011-9967-y","article-title":"Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events","volume":"32","author":"Moak","year":"2011","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib419","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(98)00493-8","article-title":"Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy","volume":"32","author":"Yetman","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib420","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.jacc.2015.03.552","article-title":"Sudden death in childhood cardiomyopathy: results from a long-term national population-based study","volume":"65","author":"Bharucha","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib421","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00246-013-0676-6","article-title":"Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study","volume":"34","author":"Kamp","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib422","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.115.017633","article-title":"Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib423","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib424","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/eurjpc\/zwab181","article-title":"External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"29","author":"Norrish","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib425","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib426","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib427","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function","volume":"72","author":"Mentias","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib428","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.amjcard.2013.12.034","article-title":"Clinical significance of late gadolinium enhancement in patients <20 years of age with hypertrophic cardiomyopathy","volume":"113","author":"Smith","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib429","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.117.032966","article-title":"Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy","volume":"138","author":"Axelsson Raja","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib430","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.117.027828","article-title":"Safety of sports for athletes with implantable cardioverter-defibrillators: long-term results of a prospective multinational registry","volume":"135","author":"Lampert","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib431","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.112.136085","article-title":"Risk stratification and outcome of patients with hypertrophic cardiomyopathy \u226560 years of age","volume":"127","author":"Maron","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib432","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib433","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.amjcard.2020.04.042","article-title":"Prediction and prevention of sudden death in young patients (<20 years) with hypertrophic cardiomyopathy","volume":"128","author":"Rowin","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib434","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib435","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jacc.2009.03.051","article-title":"Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children","volume":"54","author":"Decker","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib436","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/europace\/euy139","article-title":"Subcutaneous implantable cardioverter-defibrillator: is it ready for use in children and young adults? A single-centre study","volume":"20","author":"Silvetti","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib437","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/CIRCULATIONAHA.110.975219","article-title":"Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management","volume":"123","author":"Hauser","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib438","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/hrt.2010.217182","article-title":"The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy","volume":"98","author":"O'Mahony","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib439","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.hrthm.2016.01.001","article-title":"Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts","volume":"13","author":"Lambiase","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00392-015-0901-9","article-title":"Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience","volume":"105","author":"Frommeyer","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib441","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002488","article-title":"Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience","volume":"5","author":"Weinstock","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.02.014_bib442","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jce.13121","article-title":"Prognostic implications of defibrillation threshold testing in patients with hypertrophic cardiomyopathy","volume":"28","author":"Francia","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib443","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1253\/circj.CJ-16-0428","article-title":"Single-coil defibrillator leads yield satisfactory defibrillation safety margin in hypertrophic cardiomyopathy","volume":"80","author":"Okamura","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2024.02.014_bib444","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1540-8167.2010.01943.x","article-title":"Defibrillation thresholds in hypertrophic cardiomyopathy","volume":"22","author":"Quin","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib445","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0735-1097(96)00473-1","article-title":"Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial","volume":"29","author":"Nishimura","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib446","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/oxfordjournals.eurheartj.a015435","article-title":"Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group","volume":"18","author":"Kappenberger","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib447","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1161\/01.CIR.99.22.2927","article-title":"Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)","volume":"99","author":"Maron","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib448","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/B:JICE.0000035929.84238.2f","article-title":"Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function","volume":"11","author":"Mickelsen","year":"2004","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib449","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/europace\/euw327","article-title":"Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy","volume":"20","author":"Killu","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib450","first-page":"238","article-title":"Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy","volume":"14","author":"Gu","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib451","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejheart.2008.03.006","article-title":"Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy","volume":"10","author":"Rogers","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib452","first-page":"131","article-title":"Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy","volume":"5","author":"Rowin","year":"2019","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2024.02.014_bib453","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2017.11.040","article-title":"Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for disease-specific criteria","volume":"71","author":"Cappelli","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib454","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1161\/CIRCULATIONAHA.105.594531","article-title":"Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study","volume":"113","author":"Friedman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib455","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.jacc.2004.09.039","article-title":"Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms","volume":"44","author":"Theuns","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib456","first-page":"611","article-title":"Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study","volume":"2","author":"Kolb","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.02.014_bib457","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006937","volume":"6","author":"Peterson","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.02.014_bib458","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/europace\/euw230","article-title":"Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the D\u00e9fibrillateur Automatique Implantable-Pr\u00e9vention Primaire registry","volume":"19","author":"Defaye","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib459","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.hlc.2015.07.008","article-title":"Efficiencies and complications of dual chamber versus single chamber implantable cardioverter defibrillators in secondary sudden cardiac death prevention: a meta-analysis","volume":"25","author":"Hu","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacc.2024.02.014_bib460","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2013.01.037","article-title":"Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy","volume":"61","author":"Maron","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib461","first-page":"1499","article-title":"Long-term experience with the subcutaneous implantable cardioverter-defibrillator in teenagers and young adults","volume":"3","author":"Bettin","year":"2017","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2024.02.014_bib462","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/pace.12233","article-title":"Clinical experience of subcutaneous and transvenous implantable cardioverter defibrillators in children and teenagers","volume":"36","author":"Pettit","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib463","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.amjcard.2020.03.011","article-title":"Single coil implantable cardioverter defibrillator leads in patients with hypertrophic cardiomyopathy","volume":"125","author":"Kumar","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib464","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.hrthm.2017.11.020","article-title":"Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: a SIMPLE substudy","volume":"15","author":"Vamos","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib465","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/europace\/eus222","article-title":"2012 EHRA\/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management","volume":"14","author":"Daubert","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib466","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib467","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jacc.2018.10.044","volume":"74","author":"Kusumoto","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib468","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","article-title":"Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade","volume":"35","author":"Cohen","year":"1967","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib469","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib470","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib471","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib472","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib473","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima","year":"1986","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib474","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib475","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib476","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.02.014_bib477","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib478","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib479","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib480","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib481","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.02.014_bib482","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0002-9149(62)90373-9","article-title":"Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs","volume":"10","author":"Braunwald","year":"1962","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib483","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/adc.62.12.1265","article-title":"Cardiovascular collapse after verapamil in supraventricular tachycardia","volume":"62","author":"Kirk","year":"1987","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jacc.2024.02.014_bib484","series-title":"CAMZYOS [package insert]","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib485","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1017\/S1047951100006818","article-title":"Verapamil therapy in infants with hypertrophic cardiomyopathy","volume":"8","author":"Moran","year":"1998","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jacc.2024.02.014_bib486","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib487","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib488","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib489","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.amjcard.2013.01.340","article-title":"Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management","volume":"111","author":"Rowin","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib490","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/HCO.0000000000000200","article-title":"Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy","volume":"30","author":"Teo","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib491","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jtcvs.2011.10.096","article-title":"Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy","volume":"145","author":"Di Tommaso","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib492","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.athoracsur.2009.10.065","article-title":"Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis","volume":"89","author":"Kayalar","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib493","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","article-title":"Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"72","author":"Batzner","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib494","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","article-title":"Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort","volume":"157","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib495","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","article-title":"Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes","volume":"12","author":"Kimmelstiel","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.02.014_bib496","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2018.10.002","article-title":"Significance of pulmonary hypertension in hypertrophic cardiomyopathy","volume":"45","author":"Mitra","year":"2020","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib497","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/ehjci\/jew024","article-title":"Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy","volume":"17","author":"Ong","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib498","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","article-title":"Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes","volume":"7","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib499","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.athoracsur.2018.03.039","article-title":"Determinants of reverse remodeling of the left atrium after transaortic myectomy","volume":"106","author":"Nguyen","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib500","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/echo.13158","article-title":"Impact of septal reduction on left atrial size and diastole in hypertrophic cardiomyopathy","volume":"33","author":"Finocchiaro","year":"2016","journal-title":"Echocardiography"},{"key":"10.1016\/j.jacc.2024.02.014_bib501","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.amjcard.2015.11.016","article-title":"Usefulness of von Willebrand factor activity indexes to predict therapeutic response in hypertrophic cardiomyopathy","volume":"117","author":"Blackshear","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib502","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/jth.12780","article-title":"Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy-associated acquired von Willebrand syndrome","volume":"13","author":"Blackshear","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2024.02.014_bib503","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jtcvs.2018.03.150","article-title":"Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: potential for refinement of current criteria","volume":"156","author":"Desai","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib504","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","article-title":"Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy","volume":"28","author":"McLeod","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib505","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib506","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2009.01.079","article-title":"Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study","volume":"54","author":"Sorajja","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib507","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2011.08.040","article-title":"Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment","volume":"58","author":"Ball","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib508","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib509","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jtcvs.2018.11.148","article-title":"Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center","volume":"157","author":"Hodges","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib510","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2019.05.053","article-title":"Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy","volume":"74","author":"Cui","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib511","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mayocp.2018.07.022","article-title":"Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery","volume":"94","author":"Holst","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2024.02.014_bib512","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jacc.2016.07.735","article-title":"Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures","volume":"68","author":"Hong","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib513","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.athoracsur.2022.05.062","article-title":"Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy","volume":"114","author":"Holst","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib514","first-page":"95","article-title":"Surgical myectomy: subaortic, midventricular, and apical","volume":"37","author":"Nguyen","year":"2019","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jacc.2024.02.014_bib515","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.jtcvs.2017.10.054","article-title":"Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy","volume":"155","author":"Hang","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib516","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.athoracsur.2013.04.073","article-title":"Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy","volume":"96","author":"Kunkala","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib517","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ejcts\/ezx398","article-title":"Does septal thickness influence outcome of myectomy for hypertrophic obstructive cardiomyopathy?","volume":"53","author":"Nguyen","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib518","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.athoracsur.2012.06.008","article-title":"Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy","volume":"94","author":"Balaram","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib519","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/acs.2017.07.07","article-title":"Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience","volume":"6","author":"Rastegar","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib520","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.amjcard.2014.12.017","article-title":"Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy","volume":"115","author":"Vriesendorp","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib521","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2015.07.069","article-title":"Transaortic chordal cutting mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy","volume":"66","author":"Ferrazzi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib522","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jtcvs.2003.09.040","article-title":"Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae","volume":"127","author":"Minakata","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib523","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.athoracsur.2008.01.061","article-title":"Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes","volume":"85","author":"Kaple","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib524","doi-asserted-by":"crossref","first-page":"II122","DOI":"10.1161\/01.CIR.92.9.122","article-title":"Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus","volume":"92","author":"Schoendube","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib525","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.echo.2018.10.011","article-title":"Accuracy of jet direction on Doppler echocardiography in identifying the etiology of mitral regurgitation in obstructive hypertrophic cardiomyopathy","volume":"32","author":"Hang","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2024.02.014_bib526","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.athoracsur.2004.05.063","article-title":"Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy","volume":"78","author":"Deb","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib527","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtcvs.2014.05.028","article-title":"Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy\u2014mechanisms of obstruction and outcomes of reoperation","volume":"148","author":"Cho","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib528","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.athoracsur.2007.07.063","article-title":"Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy","volume":"85","author":"Smedira","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib529","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jtcvs.2004.08.047","article-title":"Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score","volume":"129","author":"Ralph-Edwards","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib530","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/hrt.2007.118018","article-title":"Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"94","author":"Kwon","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib531","first-page":"E58","article-title":"Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"81","author":"Sorajja","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.02.014_bib532","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2009.09.047","article-title":"Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy","volume":"55","author":"Agarwal","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib533","first-page":"107","article-title":"A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy","volume":"88","author":"Singh","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2024.02.014_bib534","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.jtcvs.2018.06.040","article-title":"Long-term results of the modified Konno procedure in high-risk children with obstructive hypertrophic cardiomyopathy","volume":"156","author":"Laredo","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib535","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2003.10.025","article-title":"Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy","volume":"93","author":"Chen","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib536","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib537","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/eht537","article-title":"Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy","volume":"35","author":"Geske","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib538","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","article-title":"Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy","volume":"111","author":"Woo","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib539","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2022.05.032","article-title":"Ventricular septal myectomy decreases long-term risk for atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"179","author":"Rowin","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib540","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/clc.23113","article-title":"Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis","volume":"42","author":"Osman","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib541","first-page":"630","article-title":"Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy","volume":"2","author":"Vriesendorp","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.02.014_bib542","first-page":"896","article-title":"A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2024.02.014_bib543","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/clc.23697","article-title":"Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: a comparison with medical therapy","volume":"44","author":"Li","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib544","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/0002-8703(85)90357-6","article-title":"Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study","volume":"109","author":"Bourmayan","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib545","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/hrt.56.6.544","article-title":"Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy","volume":"56","author":"Wilmshurst","year":"1986","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib546","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/01.CIR.79.5.1052","article-title":"Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy","volume":"79","author":"Udelson","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib547","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima","year":"1986","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib548","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF03164924","article-title":"Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy","volume":"12","author":"Sugihara","year":"1998","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib549","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2024.02.014_bib550","article-title":"Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib551","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib552","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib553","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijcard.2017.06.071","article-title":"Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"243","author":"Pelliccia","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib554","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/CIRCULATIONAHA.112.104638","article-title":"Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry","volume":"126","author":"Webber","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib555","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1161\/01.CIR.0000097110.55312.BF","article-title":"Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease","volume":"108","author":"Sorajja","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib556","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib557","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib558","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.CIR.67.2.413","article-title":"Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy","volume":"67","author":"Spicer","year":"1983","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib559","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib560","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib561","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.mayocp.2016.01.002","article-title":"The natural history of nonobstructive hypertrophic cardiomyopathy","volume":"91","author":"Hebl","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2024.02.014_bib562","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","article-title":"Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy","volume":"31","author":"Melacini","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib563","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","article-title":"Interaction of adverse disease related pathways in hypertrophic cardiomyopathy","volume":"120","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib564","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib565","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1253\/circj.CJ-16-0432","article-title":"Heart failure progression in hypertrophic cardiomyopathy\u2014possible insights from cardiopulmonary exercise testing","volume":"80","author":"Magri","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2024.02.014_bib566","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.amjcard.2012.04.030","article-title":"Cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"110","author":"Kato","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib567","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.transproceed.2013.12.052","article-title":"Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy","volume":"46","author":"Lee","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jacc.2024.02.014_bib568","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIRCHEARTFAILURE.114.001435","article-title":"Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant","volume":"7","author":"Rowin","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib569","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2024.02.014_bib570","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjcard.2017.12.044","article-title":"Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy","volume":"121","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib571","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.healun.2021.06.018","article-title":"The modified US heart allocation system improves transplant rates and decreases status upgrade utilization for patients with hypertrophic cardiomyopathy","volume":"40","author":"Fowler","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2024.02.014_bib572","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.02.014_bib573","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCHEARTFAILURE.110.959288","article-title":"Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy","volume":"4","author":"Topilsky","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib574","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MAT.0b013e318286018d","article-title":"Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case series","volume":"59","author":"Muthiah","year":"2013","journal-title":"ASAIO J"},{"key":"10.1016\/j.jacc.2024.02.014_bib575","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2015.03.012","article-title":"Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease","volume":"34","author":"Grupper","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2024.02.014_bib576","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cardfail.2017.09.011","article-title":"Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis","volume":"23","author":"Patel","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib577","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1002\/ehf2.13653","article-title":"Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction","volume":"8","author":"Yagi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib578","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib579","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejheart.2008.03.006","article-title":"Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy","volume":"10","author":"Rogers","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib580","first-page":"238","article-title":"Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy","volume":"14","author":"Gu","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib581","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacc.2017.11.040","article-title":"Cardiac resynchronization therapy for end-stage hypertrophic cardiomyopathy: the need for disease-specific criteria","volume":"71","author":"Cappelli","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib582","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/europace\/euw327","article-title":"Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy","volume":"20","author":"Killu","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib583","first-page":"131","article-title":"Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy","volume":"5","author":"Rowin","year":"2019","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2024.02.014_bib584","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jacc.2005.04.062","article-title":"Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients","volume":"46","author":"Biagini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib585","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1136\/heartjnl-2013-305471","article-title":"Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy","volume":"100","author":"Ismail","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib586","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib587","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/ehf2.13914","article-title":"Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis","volume":"9","author":"Wasserstrum","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib588","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/CIRCHEARTFAILURE.114.001843","article-title":"Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy","volume":"8","author":"Pasqualucci","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib589","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2024.02.014_bib590","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib591","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1002\/clc.20533","article-title":"Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy","volume":"33","author":"Hamada","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib592","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10554-017-1263-3","article-title":"CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase","volume":"34","author":"Cheng","year":"2018","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2024.02.014_bib593","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86898","article-title":"Molecular profiling of dilated cardiomyopathy that progresses to heart failure","volume":"1","author":"Burke","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacc.2024.02.014_bib594","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-04817-8","article-title":"Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy","volume":"608","author":"Chaffin","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2024.02.014_bib595","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCHEARTFAILURE.109.922872","article-title":"Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"3","author":"Maron","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib596","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004378","article-title":"Outcomes in patients with hypertrophic cardiomyopathy awaiting heart transplantation","volume":"11","author":"Zu\u00f1iga Cisneros","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib597","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004665","article-title":"Mechanical circulatory support device utilization and heart transplant waitlist outcomes in patients with restrictive and hypertrophic cardiomyopathy","volume":"11","author":"Sridharan","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib598","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCHEARTFAILURE.112.969980","article-title":"Current outcomes in US children with cardiomyopathy listed for heart transplantation","volume":"5","author":"Singh","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib599","series-title":"CAMZYOS [package insert]","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib600","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13048","article-title":"Outcomes of Berlin Heart EXCOR((R)) pediatric ventricular assist device support in patients with restrictive and hypertrophic cardiomyopathy","volume":"21","author":"Su","year":"2017","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jacc.2024.02.014_bib601","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1054\/jcaf.2000.9501","article-title":"Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial","volume":"6","author":"Bristow","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib602","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HCO.0b013e32831bc63b","article-title":"Resynchronization\/defibrillation for ambulatory heart failure trial: rationale and trial design","volume":"24","author":"Tang","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib603","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib604","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib605","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib606","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0735-1097(01)01727-2","article-title":"Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy","volume":"39","author":"Maron","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib607","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.chest.2018.11.009","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study","volume":"155","author":"Jung","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2024.02.014_bib608","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.jacc.2016.04.026","article-title":"Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"67","author":"Noseworthy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib609","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijcard.2017.08.010","article-title":"Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation","volume":"248","author":"Dominguez","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib610","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjcard.2016.08.092","article-title":"Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy","volume":"119","author":"van Velzen","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib611","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jce.12982","article-title":"High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device","volume":"27","author":"Wilke","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib612","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","article-title":"Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis","volume":"39","author":"Mahajan","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib613","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib614","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib615","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/eurheartj\/eht491","article-title":"Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)","volume":"35","author":"Boriani","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib616","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/europace\/euv339","article-title":"Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"18","author":"Zhao","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib617","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.hrthm.2015.03.042","article-title":"Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"12","author":"Bassiouny","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib618","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jacc.2015.08.856","article-title":"2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"67","author":"Page","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib619","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib620","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/europace\/eux163","article-title":"Device-detected subclinical atrial tachyarrhythmias: definition, implications and management\u2014an European Heart Rhythm Association (EHRA) consensus document","volume":"19","author":"Gorenek","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib621","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.115.020252","article-title":"Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes","volume":"134","author":"Swiryn","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib622","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib623","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","article-title":"Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events","volume":"20","author":"Botto","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib624","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0735-1097(10)80014-2","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study","volume":"15","author":"Robinson","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib625","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib626","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.02.014_bib627","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/pace.13310","article-title":"Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: a case series and literature review","volume":"41","author":"Moore","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib628","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.amjcard.2019.02.051","article-title":"Safety, side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy","volume":"123","author":"Miller","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib629","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/heartjnl-2016-309406","article-title":"Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"102","author":"Providencia","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib630","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence","volume":"6","author":"Santangeli","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib631","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2003.10.025","article-title":"Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy","volume":"93","author":"Chen","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib632","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jtcvs.2017.08.063","article-title":"Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy","volume":"155","author":"Bogachev-Prokophiev","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib633","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/ejcts\/ezx017","article-title":"Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathy","volume":"51","author":"Lapenna","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib634","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.316","article-title":"Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)","volume":"17","author":"Guttmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib634a","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.hrthm.2018.07.010","article-title":"Early experience with intravenous sotalol in children with and without congenital heart disease","volume":"15","author":"Vald\u00e9s","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib634b","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0002-8703(95)90079-9","article-title":"Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome","volume":"130","author":"Tanel","year":"1995","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib635","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjcard.2017.12.044","article-title":"Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy","volume":"121","author":"Rowin","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib636","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIRCHEARTFAILURE.114.001435","article-title":"Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant","volume":"7","author":"Rowin","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib637","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib638","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.hrthm.2016.03.004","article-title":"Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Santangeli","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib639","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1540-8167.2011.02183.x","article-title":"Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies","volume":"23","author":"Baquero","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib640","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FJC.0b013e31829651fe","article-title":"Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator","volume":"62","author":"Gao","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2024.02.014_bib641","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jce.13194","article-title":"Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications","volume":"28","author":"Link","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib642","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.joa.2015.12.001","article-title":"2015 HRS\/EHRA\/APHRS\/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing","volume":"32","author":"Wilkoff","year":"2016","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib643","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.hrthm.2010.05.022","article-title":"Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility","volume":"7","author":"Santangeli","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib644","first-page":"339","article-title":"Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm","volume":"4","author":"Igarashi","year":"2018","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2024.02.014_bib645","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCEP.110.957290","article-title":"Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy","volume":"4","author":"Dukkipati","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib646","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamainternmed.2013.428","article-title":"Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches","volume":"173","author":"Borne","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib647","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2024.02.014_bib648","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib649","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.hrthm.2016.03.041","article-title":"Minimally invasive posterior extrapleural thoracic sympathectomy in children with medically refractory arrhythmias","volume":"13","author":"Raskin","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib650","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hrcr.2019.10.003","article-title":"Successful bilateral thoracoscopic sympathectomy for recurrent ventricular arrhythmia in a pediatric patient with hypertrophic cardiomyopathy","volume":"6","author":"Price","year":"2020","journal-title":"HeartRhythm Case Rep"},{"key":"10.1016\/j.jacc.2024.02.014_bib651","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/0735-1097(95)00268-3","article-title":"Efficacy and proarrhythmia of oral sotalol in pediatric patients","volume":"26","author":"Pfammatter","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib652","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200002103420601","article-title":"Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"342","author":"Maron","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib653","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/jce.15739","article-title":"Clinical outcomes of radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"34","author":"Garg","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib654","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jtcvs.2017.06.002","article-title":"Electrical storms in patients with apical aneurysms and hypertrophic cardiomyopathy with midventricular obstruction: a case series","volume":"154","author":"Nguyen","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2024.02.014_bib655","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2017.2503","article-title":"Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial","volume":"317","author":"Saberi","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib656","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2047487313501277","article-title":"Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center","volume":"22","author":"Klempfner","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib657","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib658","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.117.029639","article-title":"Competitive sport participation among athletes with heart disease: a call for a paradigm shift in decision making","volume":"136","author":"Baggish","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib659","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jamacardio.2023.1042","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"8","author":"Lampert","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib660","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurheartj\/ehr092","article-title":"Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy","volume":"32","author":"Christiaans","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib661","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.07.015","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"250","author":"Dejgaard","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib662","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/bjsports-2020-101987","article-title":"Association of physical activity with all-cause and cardiovascular mortality in 7666 adults with hypertrophic cardiomyopathy (HCM): more physical activity is better","volume":"55","author":"Kwon","year":"2021","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib663","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1161\/CIRCULATIONAHA.112.000447","article-title":"Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry","volume":"127","author":"Lampert","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib664","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.117.027828","article-title":"Safety of sports for athletes with implantable cardioverter-defibrillators: long-term results of a prospective multinational registry","volume":"135","author":"Lampert","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib665","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCULATIONAHA.117.031725","article-title":"Does sport participation worsen the clinical course of hypertrophic cardiomyopathy? Clinical outcome of hypertrophic cardiomyopathy in athletes","volume":"137","author":"Pelliccia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib666","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/CIRCULATIONAHA.117.031306","article-title":"Return-to-play for athletes with genetic heart diseases","volume":"137","author":"Turkowski","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib667","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2021.04.026","article-title":"Return-to-play for athletes with long QT syndrome or genetic heart diseases predisposing to sudden death","volume":"78","author":"Tobert","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib668","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jacc.2023.05.059","article-title":"Return-to-play for elite athletes with genetic heart diseases predisposing to sudden cardiac eeath","volume":"82","author":"Martinez","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib669","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1249\/MSS.0b013e31821ece12","article-title":"2011 compendium of physical activities: a second update of codes and MET values","volume":"43","author":"Ainsworth","year":"2011","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jacc.2024.02.014_bib670","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-2008-1026080","article-title":"Ratings of perceived exertion and heart rates during short-term cycle exercise and their use in a new cycling strength test","volume":"3","author":"Borg","year":"1982","journal-title":"Int J Sports Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib671","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.117.029989","article-title":"Exercise and hypertrophic cardiomyopathy: time for a change of heart","volume":"137","author":"Saberi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib672","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2017.6","article-title":"Shared decision-making in HCM","volume":"14","author":"Maron","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib673","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.108.804617","article-title":"Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006","volume":"119","author":"Maron","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib674","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2019.03.497","article-title":"Structurally normal hearts are uncommonly associated with sudden deaths in athletes and young people","volume":"73","author":"Thiene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib675","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa1510687","article-title":"A prospective study of sudden cardiac death among children and young adults","volume":"374","author":"Bagnall","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib676","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2003.03.002","article-title":"Does sports activity enhance the risk of sudden death in adolescents and young adults?","volume":"42","author":"Corrado","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib677","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/CIRCEP.113.001376","article-title":"Pathogeneses of sudden cardiac death in National Collegiate Athletic Association athletes","volume":"7","author":"Harmon","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib678","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.amjmed.2015.12.027","article-title":"Hypertrophic cardiomyopathy as a cause of sudden cardiac death in the young: a meta-analysis","volume":"129","author":"Ullal","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib679","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacc.2011.01.049","article-title":"Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance","volume":"58","author":"Eckart","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib680","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/CIRCULATIONAHA.110.004622","article-title":"Incidence of sudden cardiac death in National Collegiate Athletic Association athletes","volume":"123","author":"Harmon","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib681","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.119.040271","article-title":"Hypertrophic cardiomyopathy-related sudden cardiac death in young people in Ontario","volume":"140","author":"Weissler-Snir","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib682","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/CIRCULATIONAHA.117.030616","article-title":"Population burden of sudden death associated with hypertrophic cardiomyopathy","volume":"136","author":"Aro","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib683","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMoa1615710","article-title":"Sudden cardiac arrest during participation in competitive sports","volume":"377","author":"Landry","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib684","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jacc.2023.01.041","article-title":"Sudden cardiac death among adolescents in the United Kingdom","volume":"81","author":"Finocchiaro","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib685","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.123.065908","article-title":"Sudden cardiac death in National Collegiate Athletic Association athletes: a 20-year study","volume":"149","author":"Petek","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib686","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.hrthm.2017.12.020","article-title":"Exercise participation and shared decision-making in patients with inherited channelopathies and cardiomyopathies","volume":"15","author":"Etheridge","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib687","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12265-020-09988-1","article-title":"Design and implementation of an emergency action plan for sudden cardiac arrest in sport","volume":"13","author":"Pelto","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.jacc.2024.02.014_bib688","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjcard.2012.12.018","article-title":"Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy","volume":"111","author":"Reineck","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib689","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000484","article-title":"Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers","volume":"3","author":"Sweeting","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib690","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The Physical Activity Guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib691","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib692","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib693","unstructured":"U.S. Department of Transportation, Federal Aviation Administration. Medical Certification. Accessed September 14, 2022. https:\/\/www.fmcsa.dot.gov\/regulations\/medical\/cardiovascular-advisory-panel-guidelines-medical-examination-commercial-motor"},{"key":"10.1016\/j.jacc.2024.02.014_bib693a","doi-asserted-by":"crossref","first-page":"s50","DOI":"10.1136\/heartjnl-2018-313058","article-title":"Heart muscle disease management in aircrew","volume":"105","author":"D'Arcy","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib694","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib695","first-page":"1248.e1","article-title":"Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and meta-analysis","volume":"32","author":"Xu","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib696","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib697","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12471-012-0358-7","article-title":"Pregnancy in women with hypertrophic cardiomyopathy","volume":"21","author":"Pieper","year":"2013","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib698","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.ajog.2019.07.019","article-title":"Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease","volume":"222","author":"Easter","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2024.02.014_bib699","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib700","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/ehx189","article-title":"Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC)","volume":"38","author":"Goland","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib701","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/heart.89.7.752","article-title":"Pregnancy related complications in women with hypertrophic cardiomyopathy","volume":"89","author":"Thaman","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib702","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.acvd.2017.05.010","article-title":"Pregnancy in women with a cardiomyopathy: outcomes and predictors from a retrospective cohort","volume":"111","author":"Billebeau","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2024.02.014_bib703","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0735-1097(02)02495-6","article-title":"Risk associated with pregnancy in hypertrophic cardiomyopathy","volume":"40","author":"Autore","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib704","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib705","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib706","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.316","article-title":"Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)","volume":"17","author":"Guttmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib707","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0735-1097(01)01727-2","article-title":"Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy","volume":"39","author":"Maron","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib708","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1515\/jpm-2021-0457","article-title":"Experience with direct oral anticoagulants in pregnancy\u2014a systematic review","volume":"50","author":"Areia","year":"2022","journal-title":"J Perinat Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib709","series-title":"CAMZYOS [package insert]","year":"2022"},{"key":"10.1016\/j.jacc.2024.02.014_bib710","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib711","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.amjcard.2013.05.070","article-title":"Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy","volume":"112","author":"Canepa","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib712","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2013.03.062","article-title":"Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy","volume":"62","author":"Olivotto","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib713","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamacardio.2019.4268","article-title":"Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy","volume":"5","author":"Fumagalli","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib714","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2009.07.030","article-title":"High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy","volume":"54","author":"Eleid","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib715","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.amjcard.2010.01.023","article-title":"Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"105","author":"Konecny","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib716","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1378\/chest.14-1498","article-title":"Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy","volume":"147","author":"Konecny","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2024.02.014_bib717","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.hrthm.2018.12.017","article-title":"Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy","volume":"16","author":"Wang","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2024.02.014_bib718","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00246-019-02145-9","article-title":"Impact of obesity on left ventricular thickness in children with hypertrophic cardiomyopathy","volume":"40","author":"Balaji","year":"2019","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib719","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib720","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib721","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCGENETICS.112.963363","article-title":"Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy","volume":"6","author":"Gruner","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib722","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/eurheartj\/ehv522","article-title":"Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers","volume":"37","author":"Claes","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.02.014_bib723","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib724","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.jcmg.2021.03.032","article-title":"Maximal wall thickness measurement in hypertrophic cardiomyopathy: biomarker variability and its impact on clinical care","volume":"14","author":"Captur","year":"2021","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib725","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib726","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jacc.2024.02.014_bib727","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib728","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.02.014_bib729","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.02.014_bib730","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib731","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib732","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib733","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2012-303271","volume":"99","author":"O'Mahony","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib734","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.298.4.405","article-title":"Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"298","author":"Maron","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.02.014_bib735","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jcmg.2020.09.037","article-title":"Progression of myocardial fibrosis in hypertrophic cardiomyopathy: a cardiac magnetic resonance study","volume":"14","author":"Habib","year":"2021","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib736","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcmg.2022.10.005","article-title":"3-Dimensional strain analysis of hypertrophic cardiomyopathy: insights from the NHLBI international HCM registry","volume":"16","author":"Heydari","year":"2023","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib737","article-title":"Radiomics of late gadolinium enhancement reveals prognostic value of myocardial scar heterogeneity in hypertrophic cardiomyopathy","author":"Fahmy","year":"2023","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2024.02.014_bib738","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/pace.13310","article-title":"Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: a case series and literature review","volume":"41","author":"Moore","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib739","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0735-1097(10)80014-2","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study","volume":"15","author":"Robinson","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib740","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.amjcard.2019.02.051","article-title":"Safety, side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy","volume":"123","author":"Miller CAS","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib741","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/heartjnl-2016-309406","article-title":"Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"102","author":"Providencia","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.02.014_bib742","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/europace\/euv339","article-title":"Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"18","author":"Zhao","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2024.02.014_bib743","first-page":"1376","article-title":"Predictors of major atrial fibrillation endpoints in the National Heart, Lung, and Blood Institute HCMR","volume":"7","author":"Kramer","year":"2021","journal-title":"J Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2024.02.014_bib744","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jacc.2019.04.021","article-title":"Pulsed field ablation for pulmonary vein isolation in atrial fibrillation","volume":"74","author":"Reddy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.02.014_bib745","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/gim.2017.218","article-title":"Adaptation and validation of the ACMG\/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen\u2019s Inherited Cardiomyopathy Expert Panel","volume":"20","author":"Kelly","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2024.02.014_bib746","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2024.02.014_bib747","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect","volume":"53","author":"Tadros","year":"2021","journal-title":"Nat Genet"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2024.08.055","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000}}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724003826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724003826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:35:37Z","timestamp":1764884137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724003826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":749,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0735109724003826"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.02.014","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Heart Association, Inc., and the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}